Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Employees - 138100, CEO - Joaquin Duato, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): 5.14, Piotroski Score(max is 10): 4, Working Capital: $3742000000, Total Assets: $192816000000, Retained Earnings: $167281000000, EBIT: 32581000000, Total Liabilities: $113539000000, Revenue: $94193000000

AryaFin Target Price - $254.71 - Current Price $ - Analyst Target Price $